Skip to main content

ACT16845 A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

NCT4913220

A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

Associated Conditions

Multiple Myeloma

Principal Investigator

Sponsor

Sanofi

The purpose of the study is to determine the antitumor activity of SAR444245 for the treatment of either advanced melanoma or cutaneous squamous cell carcinoma (CSCC) when it is administered along with another anticancer therapy: cemiplimab which belongs to a class of therapies called immune-checkpoint inhibitors (ICI), that is already approved for the treatment of CSCC and not for melanoma.

This study is currently enrolling.